LYMPHOMAS

Latest News

August 25th 2015

Dr. Mayer Discusses Patient Selection for Emerging Therapies in Patients With ER+ mBC

Ingrid A. Mayer, MD, MSCI, discusses patient selection for emerging therapies in patients with ER-positive metastatic breast cancer (mBC).

August 24th 2015

Pioneers in Hodgkin Lymphoma: Henry S. Kaplan, MD (1918-1984)

By Colin G. Evans, PhD

August 18th 2015

Hodgkin Lymphoma Label for Brentuximab Vedotin Expanded by FDA

By Silas Inman

August 17th 2015

Anti-CD30 Therapies in Lymphoma Change Treatment Decisions

By Lorraine Myers

August 10th 2015

Frits van Rhee, MD, PhD: Treatment Options

Latest Videos

Frits van Rhee, MD, PhD: Patient's Diagnosis

Frits van Rhee, MD, PhD: Significant Tests in the Diagnostic Workup

Frits van Rhee, MD, PhD: Relevant Findings from Patient's Pathology Report

Frits van Rhee, MD, PhD: Initial Presentation

David Fajgenbaum, MD, MBA, MSc: Treatment Options

David Fajgenbaum, MD, MBA, MSc: Patient's Diagnosis

David Fajgenbaum, MD, MBA, MSc: Significant Tests in the Diagnostic Workup

David Fajgenbaum, MD, MBA, MSc: Relevant Findings from Patient's Pathology Report

David Fajgenbaum, MD, MBA, MSc: Initial Presentation

Guess the Diagnosis: Case 2

CME Content

Video

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | North Carolina Oncology Association

Komal Jhaveri, MD, FACP; Ruta D. Rao, MD

Video

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | The Arizona Clinical Oncology Society

Neil M. Iyengar, MD; Kit Lu, MD

Video

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Louisiana Oncology Society

Sarah M. Tolaney, MD, MPH; Parth Khade, MD

Video

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | New Mexico Society of Clinical Oncology

Neil M. Iyengar, MD; Richard Zelkowitz, MD

Virtual Event

Kentucky Society of Clinical Oncology

2 Sessions are Available!

In-Person + Virtual Event

Breast Cancer Symposia in San Antonio

December 7, 2026

Video

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

Tiffany A. Traina, MD, FASCO; Nour Abuhadra, MD; Joshua Z. Drago, MD, MS; Ruth O’Regan, MD; Vered Stearns, MD, FASCO; Neil Vasan, MD, PhD; Anna Weiss, MD

Virtual Event

South Carolina Oncology Society

2 Sessions are Available!

Video

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Missouri Oncology Society

Neil M. Iyengar, MD; Ajit K. Bisen, MD, MBA

Video

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | New Mexico Society of Clinical Oncology

Erika P. Hamilton, MD; Katherine Sanchez, MD

Video

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Multimedia

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Video

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Tiffany A. Traina, MD, FASCO; Kevin Kalinsky, MD MS, FASCO; Mark E. Robson, MD, FASCO; Rebecca Shatsky, MD

Video

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

Video

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

William J. Gradishar, MD, FASCO, FACP; Stephanie L. Graff, MD, FACP, FASCO; Cynthia X. Ma, MD, PhD

Video

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Erika P. Hamilton, MD; Giuseppe Curigliano, MD, PhD; VK Gadi, MD, PhD; Jason Aboudi Mouabbi, MD

Video

Module 4: Breast Surgery (2025)

Eleftherios (Terry) Mamounas, MD, MPH, FACS; Michael Alvarado, MD, MS; Puneet Singh, MD, MS, FACS, FSSO, CMQ

Video

Module 5: Breast Radiation Therapy (2025)

Douglas W. Arthur, MD, FABS, FASTRO; Eleanor E. Harris, MD, FASTRO; Kathleen Horst, MD

Video

Module 3: Pathology And Biomarkers (2025)

Joyce O’Shaughnessy, MD; Sunil S. Badve, MD, FRCPath; Claudine Isaacs, MD; Michael F. Press, MD, PhD

Video

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Joyce O’Shaughnessy, MD; William J. Gradishar, MD, FASCO, FACP; N. Lynn Henry, MD, PhD, FASCO; Kevin Kalinsky, MD, MS; Joseph A. Sparano, MD; Sara Tolaney, MD, MPH

Video

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Joyce O’Shaughnessy, MD; Carol Fabian, MD; Rachel Freedman, MD, MPH; Anne Grabenstetter, MD; Claudine Isaacs, MD; Pedram Razavi, MD, PhD

Video

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

William J. Gradishar, MD, FASCO, FACP; Ting Bao, MD, MS; Jennifer A. Ligibel, MD; Filipa Lynce, MD; Ruth O’Regan, MD, MSc

Video

Module 2: Breast Imaging (2025)

Joyce O’Shaughnessy, MD; Connie Lehman, MD, PhD, FACR; David M. Schuster, MD, FACR

Video

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Joyce O’Shaughnessy, MD; Michelle Melisko, MD; Beverly Moy, MD, MPH

Video

Module 9: Toxicity Management And Survivorship Considerations (2025)

Joyce O’Shaughnessy, MD; Laura Huppert, MD; Michelle Melisko, MD; Michelle Mollica, PhD, MPH, RN, OCN; Ann H. Partridge, MD, MPH

Video

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Video

Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Kevin Kalinsky, MD, MS; Adam Brufsky, MD, PhD; Kelly Elizabeth McCann, MD, PhD; Sara Nunnery, MD, MSCI

Video

Medical Crossfire®: Optimizing 𝘌𝘚𝘙1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer

VK Gadi, MD, PhD; Neil M. Iyengar, MD; Heather McArthur, MD, MPH

Video

Coffee Talk: Charting New Pathways with HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer

Hope S. Rugo, MD, FASCO; Paolo Tarantino, MD, PhD; Alastair Thompson, MD, MBChB, BSc (Hons), FRCS (Ed), FACS

Video

Facilitating Precision Pathways: Surgical Considerations in Breast Cancer for Tackling Barriers to Genetic Testing and Targeted Therapies

Patrick I. Borgen, MD; Don S. Dizon, MD, FACP, FASCO; Kevin S. Hughes, MD, FACS; Banu Arun, MD, FASCO

Multimedia

Community Practice Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer

Neil M. Iyengar, MD; Sara M. Tolaney, MD, MPH

More News

Frits van Rhee, MD, PhD: Potential Treatment Options

August 6th 2015

Frits van Rhee, MD, PhD: Most Likely Diagnosis

August 6th 2015

Frits van Rhee, MD, PhD: Patient's Diagnostic Workup

August 6th 2015

Frits van Rhee, MD, PhD: Pathology Report Findings

August 6th 2015

Frits van Rhee, MD, PhD: Patient's Initial Presentation

August 6th 2015

David Fajgenbaum, MD, MBA, MSc: Potential Treatment Options

August 6th 2015

David Fajgenbaum, MD, MBA, MSc: Most Likely Diagnosis

August 6th 2015

David Fajgenbaum, MD, MBA, MSc: Patient's Diagnostic Workup

August 6th 2015

David Fajgenbaum, MD, MBA, MSc: Pathology Report Findings

August 6th 2015

David Fajgenbaum, MD, MBA, MSc: Patient's Initial Presentation

August 6th 2015

Guess the Diagnosis: Case 1

August 6th 2015

Guess the Diagnosis

CAR-Modified T-Cell Therapy Shows Durable Response in Non-Hodgkin Lymphoma

ByVirginia Powers, PhD

July 7th 2015

Infusions of CTL019, a CAR-modified T-cell therapy against CD19, achieved durable responses and showed an acceptable safety profile in heavily pretreated patients with CD19-positive DLBCL, MCL, and FL.

Nivolumab Safe, Effective in Relapsed/Refractory Lymphoma

June 17th 2015

Treatment with the PD-1 inhibitor nivolumab demonstrated durable objective response rates in patients with classical Hodgkin lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.

Two Doses of Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular Lymphoma

ByCatherine M. Diefenbach, MD

June 11th 2015

Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses the efficacy of two doses of polatuzumab vedotin (POV) in patients with relapsed/refractory (RR) follicular lymphoma (FL).

Lower Dose of Polatuzumab Active and Tolerable in Non-Hodgkin Lymphoma

ByWayne Kuznar

June 9th 2015

The 1.8-mg/kg dose of polatuzumab vedotin is as effective as the 2.4-mg/kg dose on the endpoint of progression-free survival in patients with relapsed/refractory non-Hodgkin lymphoma while improving tolerability, according to a pooled analysis of phase I and phase II clinical studies.

LYMPHOMAS

Latest News

Latest Videos

Frits van Rhee, MD, PhD: Patient's Diagnosis

Frits van Rhee, MD, PhD: Significant Tests in the Diagnostic Workup

Frits van Rhee, MD, PhD: Relevant Findings from Patient's Pathology Report

Frits van Rhee, MD, PhD: Initial Presentation

David Fajgenbaum, MD, MBA, MSc: Treatment Options

David Fajgenbaum, MD, MBA, MSc: Patient's Diagnosis

David Fajgenbaum, MD, MBA, MSc: Significant Tests in the Diagnostic Workup

David Fajgenbaum, MD, MBA, MSc: Relevant Findings from Patient's Pathology Report

David Fajgenbaum, MD, MBA, MSc: Initial Presentation

Guess the Diagnosis: Case 2

CME Content

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | North Carolina Oncology Association

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | The Arizona Clinical Oncology Society

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Louisiana Oncology Society

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | New Mexico Society of Clinical Oncology

Kentucky Society of Clinical Oncology

Breast Cancer Symposia in San Antonio

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

South Carolina Oncology Society

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Missouri Oncology Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | New Mexico Society of Clinical Oncology

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Medical Crossfire®: Mastering the Nuances of Early-Stage HR+/HER2- Breast Cancer—Expert Perspectives on Applying Modern Treatment Paradigms

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Module 4: Breast Surgery (2025)

Module 5: Breast Radiation Therapy (2025)

Module 3: Pathology And Biomarkers (2025)

Module 6: Adjuvant/Neoadjuvant Chemotherapy and Endocrine Therapy (2025)

Module 1: Breast Carcinogenesis & Management of High-Risk Disease (2025)

Module 7: Systemic Treatment Of Advanced/Metastatic Disease (2025)

Module 2: Breast Imaging (2025)

Module 8: Organ-Targeted Treatment of Metastatic Disease (2025)

Module 9: Toxicity Management And Survivorship Considerations (2025)

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Expanding Options, Evolving Challenges in Advanced HR+/HER2– Breast Cancer: How Experts Apply the Latest Data

Medical Crossfire®: Optimizing 𝘌𝘚𝘙1 Mutation Detection and Next-Generation Endocrine Therapy Integration in HR+/HER2– Breast Cancer

Coffee Talk: Charting New Pathways with HER2 and TROP2 Therapies – From Early to Advanced Breast Cancer

Facilitating Precision Pathways: Surgical Considerations in Breast Cancer for Tackling Barriers to Genetic Testing and Targeted Therapies

Community Practice Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer

More News

Frits van Rhee, MD, PhD: Potential Treatment Options

Frits van Rhee, MD, PhD: Most Likely Diagnosis

Frits van Rhee, MD, PhD: Patient's Diagnostic Workup

Frits van Rhee, MD, PhD: Pathology Report Findings

Frits van Rhee, MD, PhD: Patient's Initial Presentation

David Fajgenbaum, MD, MBA, MSc: Potential Treatment Options

David Fajgenbaum, MD, MBA, MSc: Most Likely Diagnosis

David Fajgenbaum, MD, MBA, MSc: Patient's Diagnostic Workup

David Fajgenbaum, MD, MBA, MSc: Pathology Report Findings

David Fajgenbaum, MD, MBA, MSc: Patient's Initial Presentation

Guess the Diagnosis: Case 1

CAR-Modified T-Cell Therapy Shows Durable Response in Non-Hodgkin Lymphoma

Nivolumab Safe, Effective in Relapsed/Refractory Lymphoma

Two Doses of Polatuzumab Vedotin in Patients With Relapsed/Refractory Follicular Lymphoma

Lower Dose of Polatuzumab Active and Tolerable in Non-Hodgkin Lymphoma

Trending on Targeted Onc

DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC

Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL

FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors

FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL

Phase 3 Results Point to a Path Forward for Cancer Vaccines